Open framework agreement on pharmaceutical discounts pursuant to § 130a para. 8 SGB V with the possibility of accession at any time, so-called admission model 2025-09
Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-09
Germany · Bochum · how to bid here →
Your path to submission
- Deadline: 5 September 2027 at 23:59 — 334 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every month (323 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Pharmazeutische Unternehmen.n = 323
- 49% of this buyer's awards went to companies that had already won here before (560 awards since 2018, spread over 286 companies). That is well below the sector norm (62%) — this buyer switches suppliers more often than others.n = 560 awards since 2018
- The award came in at a median 67% of the estimated value (5 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 5
- The median procedure drew just one bid (537 procedures with a bid count); 67% ended with a single bidder. Sector: median 2 bids.n = 537
- Across 65 procedures with structured selection criteria, this buyer most often required: Quality management (63 of 65), Trade register enrolment (63 of 65), References: services (2 of 65).n = 65
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 41 (from 962 awards).
What the buyer is looking for
This notice is intended to conclude agreements with pharmaceutical companies within the meaning of Section 130a(8) sentence 1 SGB V. The invitation to participate is addressed only to pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act. It is not an open procedure pursuant to § 15 VgV in conjunction with § 119(3) GWB, but a publication of the invitation to conclude/join/discount contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the discount. Contractual partners may become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the Pharmaceuticals Act.
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Aliud Pharma GmbH · Laichingen | 26 | 2012–2023 |
| Aristo Pharma GmbH · Berlin | 26 | 2012–2022 |
| Hexal AG · Holzkirchen | 20 | 2012–2023 |
| Glenmark Arzneimittel GmbH · Gröbenzell | 14 | 2012–2023 |
| ratiopharm GmbH | 13 | 2014–2023 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.